Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 212-338-8 | CAS number: 791-28-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Neurotoxicity
Administrative data
- Endpoint:
- neurotoxicity: acute oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: GLP guideline study
Cross-reference
- Reason / purpose for cross-reference:
- reference to same study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 981
- Report date:
- 1981
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- other: proposed guidelines of the United States Environmental Protection Agency (E.P.A) 163, 81 - 7 Acute delayed neurotoxicity study, published in the Federal Reqister on August 22, 1978, Part II, pages 37362 and 37363
- GLP compliance:
- yes
- Limit test:
- no
Test material
- Reference substance name:
- Triphenylphosphine oxide
- EC Number:
- 212-338-8
- EC Name:
- Triphenylphosphine oxide
- Cas Number:
- 791-28-6
- Molecular formula:
- C18H15OP
- IUPAC Name:
- triphenylphosphine oxide
- Details on test material:
- - Name of test material (as cited in study report): TPPO
- Physical state: white powder
- Purity: 99.6%
Constituent 1
Test animals
- Species:
- hen
- Strain:
- not specified
- Sex:
- female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Graygable Poultry Service, 12 Leech Walk, Bury St Edmunds, Suffolk
- Age at study initiation: >12 months
- Weight at study initiation: 2000-3000g
- Housing: housed in groups in floor pens in a poultry building which was designed to provide a satisfactory range of environmental conditions for this species . The pen size for the LD50 determinations was 2 .4 x 3 .1 m for 30 birds
- Diet (e.g. ad libitum): standard HRC layer diet in meal form obtained from Flowers and Son (Ramsey) Ltd ., Cambridgeshire
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 10 - 27 (mean 21)
- Humidity (%): 52-75 (63)
- Air changes (per hr): ventilation fans were adjusted as necessary
- Photoperiod (hrs dark / hrs light): 7/17
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- corn oil
- Details on exposure:
- VEHICLE
- Concentration in vehicle: 40% w/w
MEAN VOLUME APPLIED: 47.8 mL/ animal - Analytical verification of doses or concentrations:
- not specified
- Duration of treatment / exposure:
- once (as 3 doses over a 9-hour period (approximately )), with an observation period of 21 d
- Frequency of treatment:
- once
Doses / concentrations
- Remarks:
- Doses / Concentrations:
0; 7400 mg/kg bw
Basis:
actual ingested
- No. of animals per sex per dose:
- 10 females (control), 20 females (TS, two groups)
- Control animals:
- yes, concurrent vehicle
Examinations
- Positive control:
- TOCP (500 mg/kg bw)
Results and discussion
Results of examinations
- Details on results:
- Mortality:
10/20 birds died.
Symptoms:
1/10 birds dosed with TPPO at 7400 mg/kg bw showed grade 1 and 2 ataxia on days 13 and 14, respectively. However, since this bird died on day 15 it is likely that the signs of ataxia observed could be attributed to general weakness. No other birds dosed with TPPO showed any clinical signs of neurotoxicity.
All birds dosed with TOCP at 500 mg/kg showed clinical signs of neurotoxicity, with 3 birds sacrificed with Grade 8 ataxia prior to the termination of the observation period.
Body weight:
Over the post dose observation period (Days 0 to 21) birds dosed with TPPO at 7400 mg/kg showed a group mean bodyweight decrease. This decrease occurred over Days 0 to 14 with a group mean bodyweight increase over Days 14 to 21. Birds dosed with TOCP at 500 mg/kg showed a steady reduction in group mean bodyweight over the post dose observation period. The negative control birds also showed a group mean bodyweight decrease over the post dose observation period but this decrease was smaller than for the other groups of birds .
Food consumption:
Food consumption data were variable but there was evidence of a marked reduction in consumption over Days 1 to 17 for Group 3 birds (TPPO 7400 mg/kg) and Days 1 to 14 for Group 4 birds (TPPO 7400 mg/kg). There was evidence of a small reduction in the food consumption of the birds dosed with TOCP at 500 mg/kg over Days 11 to 21 when compared with Days 1 to 10. Food consumption for the Group 1 birds (Control) was within normal limits, with the exception of the food spillage which occurred over Days 8 to 10 .
Neurotoxic signs:
Signs of neurotoxicity were observed in all birds dosed with TOCP at 500 mg/kg; the first signs being observed on Day 9. Three birds with Grade 8 ataxia were sacrificed prior to the termination of the 21-day observation period.
One bird dosed with TPPO at 7400 mg/kg showed Grades 1 and 2 ataxia on Days 13 and 14 respectively. However since this bird died on Day 15 it is likely that the signs of ataxia observed could be attributed to general weakness . No other birds dosed with TPPO showed any clinical signs of neurotoxicity. No signs of ataxia were observed in any of the negative control birds.
Necropsy:
The most common observation made for the birds dosed with TPPO was the presence of muscular atrophy and three of the birds examined had a distended gall bladder. There was evidence in all groups of birds, including the negative and positive control birds, of pole areas on the endocardium and epicardium ofthe heart.
Histopathology
The morphological grades in the positive control group (TOCP 500 mg/kg) corresponded well with the clinical ataxia grades. The site of maximum damage in this group was the cervical and thoracic spinal cord. There was no evidence of neurotoxicity by TPPO, the morphological findings in these groups being undistinguishable from those in the controls.
Effect levels
- Dose descriptor:
- NOAEL
- Effect level:
- >= 7 400 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- female
- Basis for effect level:
- other: no clinical signs of neurotoxicity observed
- Remarks on result:
- other:
Applicant's summary and conclusion
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.